Other Monographs

This article provides an overview of several peptides, including AOD-9604, GHK-Cu, Epithalon, Kisspeptin-10, Selank, Semax, DSIP, MOTs-C, SS-31, and Melanotan II. While some exhibit promising investigational uses, many are flagged by the FDA for safety concerns, lack of adequate human data, or their presence in the unregulated "gray market" of wellness products. A key distinction is made between peptides with some investigational evidence and those with speculative or unproven claims, particularly for systemic use.

Regulatory Landscape and Safety Concerns

The U.S. Food and Drug Administration (FDA) has raised significant concerns regarding the safety and efficacy of numerous peptides, particularly those found in the "gray market" or compounded for off-label uses. Peptides such as AOD-9604, Melanotan II, MOTs-C, Semax, Selank, and Kisspeptin-10 are explicitly flagged due to potential issues like immunogenicity, peptide-related impurities, characterization complexity, serious adverse events, or a general lack of adequate human safety data. The FDA considers many of these substances investigational, and their use in compounding is often viewed unfavorably, especially when treated as biological products without approved Biologics License Applications (BLAs).

GHK-Cu: A Case Study

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex), also known as copper tripeptide-1 or prezatide copper acetate, is an endogenous human tripeptide. While naturally occurring, it is also synthetically manufactured for research and cosmetic applications. Despite its common use in various wellness products, there are no FDA-approved GHK-Cu drug products. It has been nominated as a bulk substance for compounding discussions under 503A but is not an approved finished drug.

Common Uses and Evidence Levels for GHK-Cu

Other Peptides Mentioned

Several other peptides are noted for their investigational status or regulatory concerns. AOD-9604 is under investigation (e.g., NCT05929066). Melanotan II is specifically listed among those with FDA safety concerns. Peptides like Epithalon, DSIP, and SS-31 are also generally categorized within this group of substances that require further rigorous investigation and regulatory clarity before widespread medical application. The overarching message from regulatory bodies is caution, emphasizing that many of these peptides lack the comprehensive safety and efficacy data required for approved medical use.

Outlook

The landscape for these peptides is characterized by ongoing scientific interest, particularly in areas like regenerative medicine and anti-aging, juxtaposed with significant regulatory scrutiny. While research continues to explore their potential therapeutic benefits, the current lack of FDA approval for most of these compounds, coupled with explicit safety warnings, underscores the need for caution. Future developments will depend heavily on robust clinical trials demonstrating both efficacy and long-term safety, moving these substances beyond the "gray market" into regulated medical applications.